Biogenetic Vesicle-Based Cancer Vaccines with Tunable Surface Potential and Immune Potency

Small. 2023 Oct;19(42):e2303225. doi: 10.1002/smll.202303225. Epub 2023 Jun 17.

Abstract

Cancer vaccines are designed to motivate antigen-specific immune responses and facilitate tumor regression with minimal side effects. To fully exert the potential of vaccines, rationally designed formulations that effectively deliver antigens and trigger potent immune reactions are urgently needed. This study demonstrates a simple and controllable vaccine-developing strategy that assembles tumor antigens into bacterial outer membrane vesicles (OMVs), natural delivery vehicles with intrinsic immune adjuvant properties, via electrostatic interaction. This OMV-delivered vaccine (OMVax) stimulated both innate and adaptive immune responses, leading to enhanced metastasis inhibition and prolonged survival of tumor-bearing mice. Moreover, the influence of different surface charged OMVax on antitumor immunity activation is investigated and declined immune response activation occurred with increased positive surface charge. Together, these findings suggest a simple vaccine formulation that can be enhanced by optimizing the surface charges of vaccine formulations.

Keywords: cancer vaccines; immunotherapy; nanotechnology; outer membrane vesicles (OMVs).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antigens
  • Cancer Vaccines*
  • Mice
  • Neoplasms* / therapy

Substances

  • Cancer Vaccines
  • Antigens
  • Adjuvants, Immunologic